Immune-Mediated Disease Flares or New-Onset Disease in 27 Subjects Following mRNA/DNA SARS-CoV-2 Vaccination
Article
[키워드] Activation
Adenoviral vector-based vaccine
adjuvanticity
Adverse
affected
age
Autoimmune
average
BNT
ChAdOx1 vaccines
condition
corticosteroid therapy
country
COVID-19
Demyelination
disease
disease expression
disease onset
disease phenotype
dose
evaluated
explained
Features
female
FIVE
flare
Immune-mediated
immune-mediated disease
immune-mediated diseases
immunization
Inflammatory
mechanism
Mild
moderate
MOST
mRNA-1273
mRNA-based vaccine
occurred
organ
Other
outcomes
over
pathogenic
Patient
receiving
Region
SARS-CoV-2
SARS-CoV-2 vaccination
SARS-CoV-2 vaccine
severity
Side effect
small fiber
the patient
the timing
therapy
TLR-7/8
USA
vaccination
Vaccine
vaccine safety
[DOI] 10.3390/vaccines9050435 PMC 바로가기 [Article Type] Article
[DOI] 10.3390/vaccines9050435 PMC 바로가기 [Article Type] Article